![[CCO] Certification Coaching Organization LLC](https://staging.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Definition
Transplant status is a clinical condition category in ICD-10-CM that captures the long-term state of a patient who has received a solid organ, tissue, or hematopoietic cell transplant. Per the FY2026 ICD-10-CM Official Guidelines (CMS), codes from subcategory Z94 (transplanted organ and tissue status) are used to indicate the presence of a functioning graft when no complication is documented. These are status codes — they reflect a patient's historical and ongoing physiological condition rather than an active disease process.
A patient with transplant status may present at any encounter for any reason; the transplant status code is reportable whenever it affects care or management. The distinction between a functioning transplant (Z94.x), a failed or rejected transplant (T86.xx), and post-transplant aftercare (Z48.2x) is critical for accurate coding, risk adjustment, and reimbursement. Chronic immunosuppression, graft-versus-host risk, and organ-specific complications make transplant status one of the most clinically significant status code families in ICD-10-CM.
Z94.x codes are not interchangeable with T86.xx complication codes. Use Z94.x only when the transplanted organ is functioning without documented rejection, failure, or infection. If any complication is documented, assign T86.xx and do not assign Z94.x for the same organ at the same encounter. See ICD-10-CM Guidelines Section I.C.19.
🗂️ Alternative Terminology
Transplant status is documented under many names across specialties. Coders and CDI specialists must recognize all variations to ensure correct code selection.
| Formal / ICD-10-CM Term | Colloquial / Clinical / Lay Terms |
|---|---|
| Kidney transplant status (Z94.0) | Renal transplant, kidney Tx, transplanted kidney, ESRD post-transplant, living-donor kidney, cadaveric kidney |
| Heart transplant status (Z94.1) | Cardiac transplant, heart Tx, orthotopic heart transplant (OHT) |
| Lung transplant status (Z94.2) | Pulmonary transplant, single-lung transplant, bilateral lung Tx, SLKT |
| Heart-lung transplant status (Z94.3) | Combined cardiopulmonary transplant, heart-lung Tx, HLT |
| Liver transplant status (Z94.4) | Hepatic transplant, orthotopic liver transplant (OLT), liver Tx, DDLT, LDLT |
| Skin transplant status (Z94.5) | Skin graft status, cutaneous graft, alloderm graft |
| Bone transplant status (Z94.6) | Bone allograft, structural bone graft |
| Corneal transplant status (Z94.7) | Penetrating keratoplasty (PK), DSEK, DMEK, corneal graft |
| Bone marrow transplant status (Z94.81) | BMT, allogeneic BMT, syngeneic BMT, myeloablative transplant |
| Intestine transplant status (Z94.82) | Intestinal transplant, bowel transplant, isolated intestinal Tx |
| Pancreas transplant status (Z94.83) | Pancreatic transplant, SPK (simultaneous pancreas-kidney), PAK (pancreas after kidney) |
| Stem cells transplant status (Z94.84) | Hematopoietic stem cell transplant (HSCT), peripheral blood stem cell transplant, autologous transplant |
| Other transplanted organ/tissue status (Z94.89) | Composite tissue allotransplantation, face transplant, hand transplant, vascular composite allograft |
| Complications of transplanted organs (T86.xx) | Rejection, graft failure, transplant infection, chronic allograft dysfunction |
| Aftercare post-transplant (Z48.2x) | Post-transplant follow-up, surveillance visit, transplant clinic visit |
🩺 Signs & Symptoms
Transplant recipients may present with symptoms related to the transplanted organ's function, rejection, infection, immunosuppressive therapy side effects, or unrelated conditions. Key clinical signs and symptoms by category include:
General / Systemic: Fatigue, malaise, unexplained fever (early rejection or infection signal), weight changes, hypertension (common with calcineurin inhibitors), hyperlipidemia, post-transplant diabetes mellitus (PTDM/NODAT).
Renal Transplant (Z94.0 / T86.1x): Rising serum creatinine, decreased urine output, new or worsening proteinuria, hematuria, graft tenderness (acute rejection), hypertension, BK virus nephropathy (BKV), recurrent glomerulonephritis in the allograft.
Heart Transplant (Z94.1 / T86.2x): Dyspnea, exercise intolerance, edema, reduced ejection fraction on echocardiogram, cardiac allograft vasculopathy (CAV), palpitations, syncope; endomyocardial biopsy is the gold standard for rejection surveillance.
Liver Transplant (Z94.4 / T86.4x): Elevated liver enzymes (AST/ALT, GGT, alkaline phosphatase), jaundice, ascites, coagulopathy, bile duct complications (stricture, leak), hepatic artery thrombosis.
Lung Transplant (Z94.2 / T86.81x–T86.83): Declining FEV1, dyspnea, cough, bronchiolitis obliterans syndrome (BOS) — hallmark of chronic rejection, recurrent respiratory infections, pleural effusion.
Bone Marrow / Stem Cell (Z94.81, Z94.84 / T86.0, T86.5): Pancytopenia, graft failure, graft-versus-host disease (GVHD) — acute (maculopapular rash, nausea, diarrhea, jaundice) vs. chronic (scleroderma-like changes, sicca symptoms, obliterative bronchiolitis), secondary malignancy, post-transplant lymphoproliferative disorder (PTLD).
Immunosuppression-Related: Opportunistic infections (CMV, Pneumocystis jirovecii pneumonia, aspergillosis, cryptococcosis), malignancy risk (skin cancers, PTLD), nephrotoxicity (calcineurin inhibitors), neurotoxicity, tremors, electrolyte imbalances.
🧭 Differential Diagnosis
Distinguishing transplant status (functioning graft) from complications and other conditions is essential for correct code assignment. The table below outlines key diagnostic differentials.
| Condition | Key Distinguishing Features | Coding Implication |
|---|---|---|
| Functioning transplant (Z94.x) | Normal or stable graft function; no documented rejection, failure, or infection; lab values at baseline | Z94.x status code only |
| Acute rejection (T86.x1) | Rapid onset rise in creatinine/enzymes; biopsy showing acute cellular or antibody-mediated rejection; treated with pulse steroids or plasmapheresis | T86.x1 (rejection); do NOT assign Z94.x for same organ |
| Chronic rejection (T86.x1 or T86.x0) | Gradual decline in function over months/years; biopsy showing fibrosis, intimal thickening; BOS for lungs; chronic allograft nephropathy for kidneys | Separate from acute — document "chronic rejection" explicitly; T86.x1 applies; chronic vs. acute distinction affects prognosis and reimbursement |
| Transplant failure (T86.x0) | Loss of graft function requiring return to dialysis (kidney) or re-listing; primary non-function | T86.x0 (failure); Z99.2 if back on dialysis |
| Post-transplant infection (T86.x3) | Positive cultures, CMV viremia, BK viruria/viremia, aspergillosis — in context of transplanted organ | T86.x3 + additional infection code (B25.x for CMV, etc.) |
| PTLD — D47.Z1 | EBV-driven lymphoproliferation in immunosuppressed transplant recipient; lymphadenopathy, B symptoms, extranodal masses | D47.Z1 + Z94.x (transplant status as additional) |
| CKD after kidney transplant | Residual chronic kidney disease in native kidneys or allograft dysfunction; only assign CKD stage if specifically documented by provider as current CKD | Do NOT assume CKD stage from creatinine alone; if functioning transplant → Z94.0; if documented CKD in allograft → N18.x + T86.1x |
| ESRD (N18.6) + dialysis (Z99.2) | Patient with kidney failure requiring ongoing dialysis; transplant history but graft not functioning | N18.6 + Z99.2; if functioning transplant replace N18.6 + Z99.2 with Z94.0 |
| GVHD (D89.81x) | Immune attack by donor cells on host tissue; skin, GI, liver involvement; acute vs. chronic; BMT context | D89.810–D89.813 (acute/chronic, grade); Z94.81 or Z94.84 as additional status code |
| Post-transplant diabetes (E13.xx) | New-onset diabetes after transplant (NODAT); steroid-induced or calcineurin inhibitor–induced | E13.xx (other specified DM) with Z79.4 (long-term insulin) if applicable; Z94.x status code additional |
Do not assign both Z94.0 (kidney transplant status) and N18.6 (ESRD) at the same encounter unless the patient has a functioning transplant AND documented ESRD in the native kidneys or documented allograft dysfunction. Per ICD-10-CM Official Guidelines, a functioning kidney transplant means ESRD has been treated — do not assign ESRD with a functioning graft.
📋 Clinical Indicators for Coders/CDI
Use the following indicators to identify transplant status coding opportunities in the health record. These triggers help CDI specialists ensure complete and accurate capture at every encounter.
| Clinical Indicator | Documentation Needed | Action |
|---|---|---|
| Past medical history: "s/p kidney transplant" or "renal Tx 2018" | Confirm still functioning; no current rejection or failure documented | Assign Z94.0 if functioning; query if unclear |
| Immunosuppressant medications listed (tacrolimus, cyclosporine, mycophenolate) | Transplant type and organ; functioning status of graft | Assign Z94.x + Z79.624 or Z79.52 as applicable |
| Rising creatinine or declining organ function labs | Provider interpretation: rejection vs. infection vs. toxicity vs. medication effect | Query for etiology; do not code "rejection" without physician documentation |
| Renal biopsy ordered or performed | Biopsy result + provider interpretation (acute vs. chronic rejection, infection, toxicity) | Await pathology result before assigning T86.1x; query if not documented |
| Transplant clinic visit (Z48.2x) | Type of organ transplanted; aftercare vs. complication visit; any complications noted | Assign Z48.2x for routine aftercare; switch to T86.xx if complication found |
| BK virus detected (viruria or viremia) | Provider documentation of BK nephropathy or BK viremia affecting graft | T86.19 (other complication of kidney transplant) + B97.89 (other viral agent); query for specificity |
| PTLD work-up or diagnosis | Pathology confirming PTLD; transplant type | D47.Z1 + Z94.x for transplant status; add Z79.624 for immunosuppression |
| Patient on dialysis with prior kidney transplant | Is the transplant functioning? Graft failure documented? | If graft failed → T86.10 or T86.11; assign Z99.2 + N18.6 if ESRD returned |
| Laterality for kidney transplant | Which kidney was transplanted (right/left iliac fossa)? Native kidneys still present? | ICD-10-CM does not provide laterality for Z94.0, but document for medical necessity and query for native kidney status |
| Acute vs. chronic rejection documentation | Explicit provider statement of acute or chronic rejection | Critical distinction — affects T86.xx specificity and reimbursement |
When immunosuppressant medications are listed in the medication reconciliation but no transplant status code appears in the problem list or encounter documentation, initiate a query: "The chart reflects long-term immunosuppressant therapy (e.g., tacrolimus, mycophenolate). Does the patient have a history of organ or tissue transplantation? If so, please specify the organ transplanted and whether the graft is currently: (a) functioning, (b) rejected, (c) failed, or (d) not applicable."
🦴 Anatomy & Pathophysiology
Solid Organ Transplantation: Organ transplantation replaces a failed or failing native organ with an allograft from a deceased or living donor. The transplanted organ is surgically anastomosed to the recipient's vasculature and, for kidney transplants, to the urinary system. The allograft is recognized as foreign by the recipient's immune system, making lifelong immunosuppression necessary to prevent rejection.
Rejection Mechanisms: Rejection is classified by timing and mechanism per UpToDate clinical references:
- Hyperacute rejection: Occurs within minutes to hours; mediated by preformed antibodies; rare with modern crossmatch testing.
- Acute cellular rejection (ACR): T-cell–mediated; typically within weeks to months; treated with high-dose corticosteroids and, if severe, antithymocyte globulin (ATG).
- Antibody-mediated rejection (AMR): Donor-specific antibodies (DSA) attack vascular endothelium; treated with plasmapheresis, IVIG, rituximab.
- Chronic rejection / chronic allograft dysfunction: Progressive fibrosis and vascular changes over years; manifests as bronchiolitis obliterans syndrome (BOS) in lungs, cardiac allograft vasculopathy (CAV) in hearts, and chronic allograft nephropathy in kidneys; less amenable to treatment.
Hematopoietic Cell Transplantation (HCT): Bone marrow (BMT) and peripheral blood stem cell transplants (Z94.81, Z94.84) replace the recipient's hematopoietic system. Allogeneic transplants carry risk of graft-versus-host disease (GVHD) in addition to graft failure. The graft-versus-leukemia (GVL) effect is therapeutically beneficial. Autologous transplants (using the patient's own cells) carry no GVHD risk but higher relapse risk.
Immunosuppression Pharmacology: Standard immunosuppression typically involves a calcineurin inhibitor (tacrolimus or cyclosporine), a purine synthesis inhibitor (mycophenolate mofetil or azathioprine), and corticosteroids. Maintenance regimens are lifelong for solid organs. mTOR inhibitors (sirolimus, everolimus) may substitute or supplement calcineurin inhibitors. Complications of immunosuppression include nephrotoxicity, neurotoxicity, hypertension, hyperlipidemia, bone loss, PTDM, and increased infection and malignancy risk.
Post-Transplant Lymphoproliferative Disorder (PTLD): PTLD (D47.Z1) is a spectrum of lymphoid proliferations driven by Epstein-Barr virus (EBV) reactivation in the setting of immunosuppression. It ranges from benign polyclonal hyperplasia to aggressive monomorphic PTLD resembling diffuse large B-cell lymphoma. Incidence is highest in the first year post-transplant. Treatment includes reduction of immunosuppression, rituximab, and chemotherapy for aggressive forms.
💊 Medication Impact / Treatment
Transplant recipients require lifelong medication management. The following drug classes and specific agents are central to transplant care and have significant coding implications.
Calcineurin Inhibitors: Tacrolimus (Prograf, Astagraf) and cyclosporine (Sandimmune, Gengraf) are the backbone of solid organ immunosuppression. Nephrotoxicity is a major concern — rising creatinine may represent calcineurin inhibitor toxicity rather than rejection; this distinction must be documented. HCPCS codes J7502 (cyclosporine oral) and J7507/J7508 (tacrolimus) apply to facility-administered doses.
Antiproliferative Agents: Mycophenolate mofetil (CellCept, J7517) and mycophenolic acid (Myfortic, J7518) inhibit purine synthesis. Azathioprine is an older alternative. These agents reduce rejection risk but increase infection susceptibility.
mTOR Inhibitors: Sirolimus (Rapamune, J7520) and everolimus (Zortress, J7527) inhibit the mammalian target of rapamycin pathway. Used in calcineurin inhibitor–sparing regimens or as primary immunosuppression in select patients.
Corticosteroids: Prednisone and methylprednisolone are used for maintenance (Z79.52 systemic steroids) and rejection treatment (pulse dosing). Long-term use contributes to PTDM, osteoporosis, adrenal suppression, and Cushingoid features. Coding: Z79.52 (long-term systemic steroids) should be assigned when chronic steroid use affects management.
Anticoagulants and Antiplatelet Agents: Some transplant patients require anticoagulation (Z79.01 long-term anticoagulant use). Distinguish Z79.01 (anticoagulants) from Z79.02 (antithrombotics/antiplatelet) for accurate coding.
Immunomodulators: Z79.624 (long-term use of immunomodulators) applies to immunosuppressive drugs used to maintain graft function. This Z code should be assigned at every encounter where immunosuppressants are documented as current medications.
Prophylactic Antimicrobials: Post-transplant patients typically receive prophylaxis against CMV (valganciclovir), Pneumocystis (trimethoprim-sulfamethoxazole), fungal infections (fluconazole, voriconazole), and toxoplasmosis. These represent additional code opportunities (Z79.2 long-term antibiotic use; individual drug codes).
Immunosuppressant medications listed in the medication reconciliation are a clinical indicator for transplant status codes (Z94.x) and Z79.624. Auditors should verify that when tacrolimus, mycophenolate, or cyclosporine appears in the medication list, a corresponding transplant status code is present. Failure to capture Z94.x represents a significant RAF gap — Z94.0 kidney transplant status maps to HCC 370 (CMS v28) with meaningful risk score impact.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
🔒 Register or sign in to read the full guide
Unlock the full guide including:
- • 📘 ICD-10-CM Guidelines (FY2026)
- • 🔢 ICD-10-CM Code Set (FY2026)
- • 🔎 Indexing
- • 🏥 CPT (2026)
- • 🧾 HCPCS (2026)
- • 📚 AHA Coding Clinic (Recent Guidance)
- • 💰 HCC / Risk Adjustment (v28)
- • ✍️ CDI Query Templates
- • 🧑⚕️ Treatments (Clinical)
- • 🎓 Patient Education / Summary
